Chronic kidney disease: a high-risk group that deserves intensive lipid lowering
Author:
Affiliation:
1. Brigham and Women’s Hospital, Cardiovascular Innovation, 360 Longwood Ave, 7th Floor, Boston, MA 02115, USA
Publisher
Oxford University Press (OUP)
Subject
Cardiology and Cardiovascular Medicine
Link
http://academic.oup.com/eurheartj/article-pdf/41/42/4124/36172022/ehaa550.pdf
Reference12 articles.
1. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins;Baigent;Lancet,2005
2. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS);Mach;Eur Heart J,2020
3. Low density lipoprotein: lower is totally better;Cannon;J Am Coll Cardiol,2020
4. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis;Matsushita;Lancet,2010
5. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization;Go;N Engl J Med,2004
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Focus on trials: dementia, lipids, thrombosis, and heart failure;European Heart Journal;2022-12-21
2. Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from G etting to an impr O ved U nderstanding of L ow‐ D ensity lipoprotein cholesterol and dyslipidemia management ( GOULD );Clinical Cardiology;2022-09-19
3. Natural killer T cell/IL-4 signaling promotes bone marrow-derived fibroblast activation and M2 macrophage-to-myofibroblast transition in renal fibrosis;International Immunopharmacology;2021-09
4. New challenges in the management of acute coronary syndromes: residual risk and sex-related inequalities;European Heart Journal;2020-11-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3